insights_auto
Why is AXGN down ५.२४%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
US$ ४८.६६
arrow_downward
-५.२४%(-२.६९) 1D
नोभेम्बर ५, १५:४८:३७ GMT-५ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
US$ ५१.६२
High
US$ ५१.८५
Low
US$ ४७.५७
Mkt. cap
२.९१ अरब
Avg. vol.
१७.८० लाख
Volume
७.४९ लाख
52-wk high
US$ ५२.९१
52-wk low
US$ २३.००
EPS
-US$ ०.६८
Beta
१.२१
Shares outstanding
५.९७ करोड
No. of employees
६२२
Open
US$ ५१.६२
High
US$ ५१.८५
Low
US$ ४७.५७
Mkt. cap
२.९१ अरब
Avg. vol.
१७.८० लाख
Volume
७.४९ लाख
52-wk high
US$ ५२.९१
52-wk low
US$ २३.००
EPS
-US$ ०.६८
Beta
१.२१
Shares outstanding
५.९७ करोड
No. of employees
६२२
News stories
From web sources and news partners
WSJ
·
४६ मिनेट पहिले
Your House vs. the Stock Market: Which Has Been a Better Investment?
KSL
·
१० मिनेट पहिले
A wipeout for AI stocks sends Wall Street reeling, and the S&P 500 tumbles more than 3%
ChartMill
·
४३ मिनेट पहिले
S&P 500 Top Movers: Gainers and Losers in Nov. 5, 2026 Session
The Washington Post
·
४४ मिनेट पहिले
Stocks tumble, erasing post-midterm gains as markets weigh future of AI build-out
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees६२२
Founded२००२
HeadquartersAlachua, फ्लोरिडा, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websiteaxogeninc.com